IceCure Medical
Tel Aviv, Israel· Est.
IceCure provides a liquid‑nitrogen cryoablation platform for minimally invasive tumor destruction across multiple oncology indications.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $120M
AI Company Overview
IceCure provides a liquid‑nitrogen cryoablation platform for minimally invasive tumor destruction across multiple oncology indications.
OncologyInterventional Oncology
Technology Platform
ProSense® liquid‑nitrogen cryoablation system delivering rapid, ultra‑cold temperatures via a single needle‑like cryoprobe for minimally invasive tumor destruction.
Opportunities
Expansion of FDA‑cleared indications, adoption in outpatient oncology centers, and leveraging the aging population’s preference for minimally invasive procedures.
Risk Factors
Regulatory clearance for new indications, reimbursement variability across regions, and competition from alternative ablation technologies.
Competitive Landscape
Key competitors include Galil Medical, HealthTronics, and CryoPen, but IceCure differentiates through its liquid‑nitrogen platform, single‑probe simplicity, and FDA‑cleared breast cancer indication.